PRIMARY PERITONEAL CAVITY CANCER
Clinical trials for PRIMARY PERITONEAL CAVITY CANCER explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CAVITY CANCER trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CAVITY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests whether combining two drugs, senaparib and temozolomide, can shrink tumors in people with a certain type of ovarian cancer linked to an ARID1A gene change. About 18 adults with recurrent or persistent clear cell or endometrioid ovarian, fallopian tube, or primary…
Matched conditions: PRIMARY PERITONEAL CAVITY CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New drug XMT-1660 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new drug called XMT-1660 in people with advanced solid tumors, including triple-negative breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. About 319 participants will receive the drug to…
Matched conditions: PRIMARY PERITONEAL CAVITY CANCER
Phase: PHASE1 • Sponsor: Mersana Therapeutics • Aim: Disease control
Last updated May 11, 2026 20:52 UTC